NASDAQ · Biotechnology · USD

Molecular Partners AG (MOLN) Stock Analysis

Molecular Partners AG (MOLN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

MOLN

$3.72

+$0.02 (+0.54%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MOLN with… →

MOLN Key Statistics

As of Oct 21, 2026

Trading

Open: $3.75
Previous Close: $3.70
Day's Range: 3.72–3.80
52-Week Range: 3.52–5.36
Volume: 3.14K
Beta: 0.69

Valuation

Market Cap: $142.50M
P/E Ratio: unprofitable
EPS (ttm): −1.71

Financials (FY)

Revenue (FY): $0.00−100.00%
Net Income (FY): −$61.65M
Shares Outstanding: 38.31M
1-Year Return: +0.54%

Dividend and dates

Avg Volume: 1.26K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, MOLN closed at $3.72, +0.54% over 1 year.

Molecular Partners AG (MOLN) has a market capitalization of $142.50M.

In fiscal 2025, MOLN reported revenue of $0.00.

MOLN Stock Return by Calendar Year

Molecular Partners AG (MOLN) return since Jun 2021: what $10,000 became

1 year: $10,000 $10,054; +0.54%
5 years: $10,000 $1,947; −80.53%
Since Jun 2021: $10,000 $1,893; −81.07%

If you had invested $10,000 in Molecular Partners AG (MOLN) at the close on June 16, 2021, the earliest close on record here, it would have been worth $1,893 at the close on October 21, 2026: −81.07% in total, −26.75% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−2.39%−65.85%−36.18%+13.59%−8.19%−14.66%

2021*20222023202420252026*

Year	Return
2026 (partial year)	−14.66%
2025	−8.19%
2024	+13.59%
2023	−36.18%
2022	−65.85%
2021 (partial year)	−2.39%

As of October 21, 2026.

MOLN Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$61.65M	—
2024	$4.97M	−$54.04M	−1,087.4%
2023	$7.04M	−$61.98M	−880.7%
2022	$189.56M	$117.85M	62.2%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$55.44M	−$61.65M	—
2024	$4.97M	—	−$61.22M	−$54.04M	−1,087.4%
2023	$7.04M	—	−$61.11M	−$61.98M	−880.7%
2022	$189.56M	—	$116.61M	$117.85M	62.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Analysis

Data-derived

Company Overview

Molecular Partners AG (MOLN) is capitalised at $142.50M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 134.

MOLN last closed at $3.72 on October 21, 2026. That is +$0.02 (+0.54%) against the previous close. Over the past 52 weeks the price has ranged from $3.52 to $5.36. The latest close sits 5.68% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. Against the prior fiscal year total of $4.97M, that is a change of −100.00%. The same year closed with a net loss of $61.65M. Trailing earnings per share are −1.71.

Across the 4 fiscal years on file, revenue moves from $189.56M in 2022 to $0.00 in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 0.69. Daily returns over the trailing 5 years annualize to a volatility of 78.3%. The trailing one-year total return is +0.54%. Across 5 years the annualized return works out at −27.91%.

Growth & Income

The record shows no dividend for MOLN.

The strongest complete calendar year on file is 2024 at +13.59%; the weakest is 2022 at −65.85%. Of the 4 complete calendar years on file, 1 finished higher. So far in 2026 the total return is −14.66%.

Peer Comparison

Molecular Partners AG (MOLN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Molecular Partners AG	MOLN	$142.50M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. Molecular Partners AG has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Molecular Partners AG

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Visit website →